

Noncompeting Continuation Application Content

In compliance with 45 CFR 74.121(d) and 92.10(b)(4), as applicable, noncompeting continuation applications submitted within the project period need only include:

A. A brief progress report that describes the accomplishments of the previous budget period.

B. Any new or significantly revised items or information (objectives, scope of activities, operational methods, evaluation, etc.) not included in the Year 01 application.

C. An annual budget and justification. Existing budget items that are unchanged from the previous budget period do not need rejustification. Simply list the items in the budget and indicate that they are continuation items. Supporting justification should be provided where appropriate.

Executive Order 12372 Review

Applications are subject to Intergovernmental Review of Federal Programs as governed by Executive Order (E.O.) 12372. E.O. 12372 sets up a system for State and local government review of proposed Federal assistance applications. Applicants should contact their State Single Point of Contact (SPOC) as early as possible to alert them to the prospective applications and receive any necessary instructions on the State process. For proposed projects serving more than one State, the applicant is advised to contact the SPOC of each affected State. A current list of SPOCs is included in the application kit. If SPOCs have any State process recommendations on applications submitted to CDC, they should send them to Sharron P. Orum, Grants Management Officer, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 314, Mailstop E-18, Atlanta, GA 30305, no later than 60 days after the application deadline date. The Program Announcement Number and Program Title should be referenced on the document. The granting agency does not guarantee to "accommodate or explain" State process recommendations it receives after that date. Indian tribes are strongly encouraged to request tribal government review of the proposed application. If tribal governments have any tribal process recommendations on applications submitted to CDC, they should forward them to Sharron P. Orum, Grants Management Officer, Grants Management Branch, Centers for Disease Control and Prevention (CDC),

255 East Paces Ferry Road, NE., Room 314, Mailstop E-18, Atlanta, GA 30305. This should be done no later than 60 days after the application deadline date. The granting agency does not guarantee to "accommodate or explain" for tribal process recommendations it receives after that date.

Public Health System Reporting Requirements

This program is not subject to the Public Health System Reporting Requirements.

Catalog of Federal Domestic Assistance Number

The Catalog of Federal Domestic Assistance Number is 93.283.

Other Requirements

Paperwork Reduction Act

Projects that involve the collection of information from 10 or more individuals and funded by the cooperative agreement will be subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act.

Application Submission and Deadline

The original and two copies of the application PHS Form 5161-1 (Revised 7/92, OMB Number 0937-0189) must be submitted to Sharron P. Orum, Grants Management Officer, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 314, Mail Stop E-18, Atlanta, GA 30305 on or before July 1, 1997.

1. *Deadline:* Applications shall be considered as meeting the deadline if they are either:

(a) Received on or before the deadline date; or

(b) Sent on or before the deadline date and received in time for submission to the objective review group. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

2. *Late Applications:* Applications that do not meet the criteria in 1.(a) or 1.(b) above are considered late applications. Late applications will not be considered and will be returned to the applicant.

Where To Obtain Additional Information

A complete program description, information on application procedures, an application package and business management technical assistance may

be obtained from Glynnis D. Taylor, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 314, Atlanta, GA 30305, telephone (404) 842-6593, fax (404) 842-6513, or Internet or CDC WONDER electronic mail at gld1@cdc.gov.

Programmatic technical assistance may be obtained from Kathryn Sunnarborg or William Thomas, Technical Information Specialist, Technical Information and Editorial Services Branch, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), Mailstop K-13, 4770 Buford Highway, NE., Atlanta, GA 30341-3724, telephone (770) 488-5080.

Please refer to Announcement Number 766 when requesting information and submitting an application.

You may obtain this and other announcements from one of two sites on the actual publication date: CDC's homepage at <http://www.cdc.gov> or the Government Printing Office homepage (including free on-line access to the **Federal Register** at <http://www.access.gpo.gov>).

Potential applicants may obtain a copy of "Healthy People 2000" (Full Report, Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report, Stock No. 017-001-00473-1) referenced in the "Introduction" through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: May 16, 1997.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-13422 Filed 5-21-97; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Government-Owned Inventions; Availability for Licensing

AGENCY: Office of Technology Transfer, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

The inventions named in this notice are owned by agencies of the United

States Government and are available for licensing in the United States (U.S.) in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to Marjorie Hunter, Licensing Specialist at the Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Mailstop E-67, 1600 Clifton Rd., Atlanta, GA 30333, telephone (404) 639-6271; facsimile (404) 639-6266. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Methods and Compositions for an Artificial Lung Organ Culture System

Quinn, F. D.; Birkness, K. A.
Filed 23 September 94
Serial No. 08/679,081 (Ref # E-14)

Methods have been developed creating an artificial lung culture system, comprised of multiple human cell layers, for studying the passage of pathogens and chemical substances through the organ. The system is comprised of an endothelial cell layer and an alveolar epithelial cell layer oriented on either side of, and in direct contact with, an artificial microporous membrane. This stable culture system provides a more complex system for study than simple monolayers of human cells or animal models. The culture system is easily maintained without the use of antibiotics and is viable for longer periods of time than other models. (*Portfolio:* Human Organ, Tissue Culture, Liver.)

Infectious cDNA Clones for Dengue Virus: Strain 16881 and Live Attenuated Vaccine Derivative, Strain PDK-53

Kinney, R. M.; Gubler, D. J.; Trent, D. W.; Halstead, S. B.; Chang, J.; Butrapet, S.; Bhamarapravati, N.
Filed 7 June 95
Serial No. 08/483,292 (Ref # E-132-95/0)

A quadravalent vaccine which evokes immunity against all four serotypes of dengue virus comprising DEN-2 PDK-53 infectious clone derivative, DEN-2/1, DEN-2/3, or DEN-2/4 viruses, and related methods of immunization are described in this invention. The invention also provides a method of cloning and sequencing a cDNA copy of

an entire RNA genome of the PDK-53 vaccine derivative of dengue 2 virus, strain 16881, which can be used to engineer new dengue vaccines as well as recombinant chimeric viruses. This invention provides a host cell with multiple constructs of protein encoded by several nucleotide sequences. (*Portfolio:* Vector-borne Infectious Diseases, Vaccine, Dengue, Chimeric Viruses.)

SecA Gene of Mycobacterium Tuberculosis and Related Methods and Compositions

Quinn, F. D.; Owens, M. H.; King, C. H.
Filed 22 February 95
Serial No. 08/394,646 (Ref # E-066-95/0)

This invention includes an isolated nucleic acid encoding a SecA protein of *Mycobacteria tuberculosis*. This nucleic acid can be a native coding sequence for the SecA protein or any alternative coding sequence for the SecA protein of *M. Tuberculosis*. An isolated fragment of the secA gene that is specific for *M. Tuberculosis* is also provided. A purified SecA protein of *M. Tuberculosis* which comprises the sequence set forth in the Sequence Listing as SEQ ID NO: 2 is provided. Fragments of the *M. Tuberculosis* SecA protein, a purified mutant SecA protein of *M. Tuberculosis*, and a purified mutant *M. Tuberculosis* expressing the mutant SecA protein are provided in the invention.

The invention provides methods of screening for putative *M. Tuberculosis* virulence factors translocated by the SecA protein. In one example of the method (the method comprises: inhibiting the translocation ATPase activity of the *M. Tuberculosis* SecA protein, and detecting the accumulation of precursor forms of proteins in the cytoplasm of the *M. Tuberculosis* cells) the accumulation of a precursor indicating the presence of a translocation ATPase activity of the *M. Tuberculosis* SecA protein can be inhibited by administering an amount of sodium azide to *M. Tuberculosis* cells or by mutating the secA gene so that it produces a non-lethal translocation ATPase deficient *M. Tuberculosis* mutant.

Treating HIV Infection by Inhibiting Bcl-2

Sandstrom, P. A.; Folks, T. M.
Filed 29 January 96
Serial No. 08/593,407 (Ref # E-102-95/0)

This invention provides a method of treating an HIV infection by inhibiting Bcl-2 expression or activity. This invention also provides a method of

screening for a compound that inhibits HIV replication. This invention also provides a cell line transfected with a nucleic acid that encodes Bcl-2, wherein the cell line expresses bcl-2, and the cell line is infected with HIV. (*Portfolio:* HIV, AIDS, Viral Infection, Cellular Biology.)

Methods for Sensitive Detection of Reverse Transcriptase Activity

Heneine, W.; Folks, T. M.; Switzer, W. M.; Yamamoto, S.
Filed 27 January 95
Serial No. 08/379,851 (Ref # E-232-93/0)

This invention provides a method for detecting a retrovirus in a biological sample by identifying the presence of the enzyme reverse transcriptase (RT). This RT assay employs a PCR-based amplification system to detect a known cDNA product of the RT reaction. This invention is highly sensitive and specific and requires no knowledge of viral genomic sequence. Retroviruses that previously would have gone undetected may now be identified. (*Portfolio:* PCR, Reverse Transcriptase, Retrovirus, Diagnosis.)

Nucleotide Sequences of New Hantavirus—"Bayou Virus"

Nichol, S.; Morzunov, S.; Ksiazek, T.; Rollin, P.; Spiropoulou, C.
Filed 17 February 95
Serial No. 08/390,888 (Ref # E-183-93/2)

Nucleotide sequences of the M and S segments of the Louisiana virus genome have been identified. Included are several different methods of detecting the "Bayou" hantavirus and isolated nucleic acids specific for the "Bayou" hantavirus. Purified antigenic polypeptides and antibodies that specifically bind to the "Bayou" hantavirus or those polypeptides are provided. (*Portfolio:* Hantavirus, Bayou.)

Nucleic Acids of a Novel Hantavirus and Reagents for Detection and Prevention of Infection. The "Sin Nombre" Hantavirus

Rollin, P.; Elliott, L.; Ksiazek, T.; Nichol, S.
Filed 24 June 94
Serial No. 08/569,242 (Ref # E-183-93/3)

This invention describes a nucleotide sequence for a new hantavirus, referred to as "Sin Nombre" hantavirus, which is the causative agent of hantavirus pulmonary syndrome. A method of detection of the "Sin Nombre" hantavirus and an associated method of prevention of infection is provided. The

"Sin Nombre" virus strain was previously known as the "Muerto Canyon" hantavirus. (*Portfolio*: Hantavirus, Diagnosis.)

The Black Creek Canal Strain of Hantavirus and Methods of Detection and Prevention of Infection Therefrom

Nichol, S. T.; Elliott, L.; Ksiazek, T. G.; Morzunov, S.; Ravkov, E.; Rollin, P. E. Filed 17 February 95
Serial No. 08/390,361 (Ref # E-183-93/4)

The Black Creek Canal strain of hantavirus, which is responsible for a case of hantavirus Pulmonary Syndrome in Florida, is provided. The virus was isolated from a rodent and is genetically different at the nucleotide level from the Muerto Canyon virus. The invention also provides purified polypeptides encoded by the nucleic acids, purified antibodies that bind the hantavirus, and describes methods of detection and prevention. (*Portfolio*: Hantavirus, Vaccine, Black Creek Canal Strain.)

Method and Composition for Diagnosing Cat Scratch Disease and Bacillary Angiomatosis Caused by Rochalimaea Henselae (Now Referred to as Bartonella Henselae)

Regnery, R. L.; Anderson, B.E. Patent Issued: 21 March 95
Patent No. 5,399,485 (Ref # E-048-92/0)

This invention provides a method of diagnosing cat scratch disease and bacillary angiomatosis by detecting the presence of *Bartonella henselae* or an immunogenically specific determinant thereof in humans or animals. Also provided is a vaccine comprising an immunogenic amount of a nonpathogenic *Bartonella henselae* and a pharmaceutically acceptable carrier. (*Portfolio*: Vaccine, Cat Scratch Disease, Bartonella.)

Method for Detection of a New Marker Associated With Hepatitis Delta Virus Infection

Fields, H. A.; Khudyakov, Y.; Favorov, M. Patent Issued: 29 August 95
Patent No. 5,445,932 (Ref # E-069-92/0)

Reagents and methods for the detection of a marker which is associated with severe forms of hepatitis delta have been developed. This invention detects the presence of anti-HDAg' antibodies in a biological sample. It also describes a vaccine comprised of immunogenically active HDAg' polypeptides in a pharmaceutically acceptable carrier. (*Portfolio*: Hepatitis Delta, Vaccine, Diagnosis.)

DNA Sequence Encoding a Cynomolgus Monkey Hepatitis A Virus Capsid Protein

Nainan, O. V.; Margolis, H. S.; Robertson, B. H.; Brinton, M. A.; Ebert, J. W. Patent Issued: 4 July 95
Patent No. 5,430,135 (Ref # E-089-91/1)

This invention relates to substantially pure preparations of the cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55, which may be used in the prevention of hepatitis A in animals. This invention provides a virus that may be adapted in a cell-line suitable for human vaccine development or may be cloned into an expression vector in which the cDNA coding for the capsid region of the virus may provide a virus-like antigen which could substitute for the whole virus. (*Portfolio*: Hepatitis A, Diagnosis, Vaccine.)

Nucleic Acid Probes and Methods for Detecting Candida DNA Cells in Blood

Lot, T. J.; Morrison, C. J.; Reiss, E.; Lasker, B.; Zakroff, S. Patent Issued: 20 June 95
Patent No. 5,426,027 (Ref # E-118-93/0)

An isolated double-stranded nucleic acid sequence specific for *Candida albicans*, as well as ITS2 sequences for *C. Parapsilosis*, *C. Tropicalis*, *C. Glabrata* and *C. Krusei*, is provided. This invention also contemplates an isolated nucleic acid that specifically hybridizes with, or selectively amplifies, a nucleic acid of *C. albicans*. These sequences may be used in a rapid method of diagnosing systemic candidiasis in patients by detecting *C. albicans* in blood samples with concentration as low as 10 cells per ml. (*Portfolio*: Nucleic Acid Sequencing, Candida, Diagnostics.)

Ear Based Hearing Protector/Communication System

Franks, J. R.; Sizemore, C. W.; Dunn, D. E. Patent Issued: 20 June 95
Patent No. 5,426,719 (Ref # E-154-91/0)

A combination hearing protector and communication device which may be incorporated into earmuffs/earplugs has been developed. The system allows dual channels and does not compromise the noise-reducing characteristics of normal earmuffs or earplugs. The system incorporates an independent transmission channel with the wearer having the possibility of receiving the same channel as other wearers. (*Portfolio*: Ear Protection, Communication, Hearing Safety.)

PsaA

Russell, H.; Sampson, J.; O'Connor, S.

Patent Issued: 6 June 95
Patent No. 5,422,427 (Ref # E-157-91/0)

The patent claims a DNA sequence encoding a pneumococcal surface adhesin A protein (PsaA), formerly designated as pneumococcal fimbrial protein. This sequence may be utilized to relates to produce a PsaA polypeptide. The sequence may also be utilized to design diagnostics for measuring the amount of PsaA contained in a sample. Vaccines which may be efficacious in adults or children may be developed using the sequence or polypeptides. (*Portfolio*: Vaccine, Diagnosis, Pneumococcal Surface Adhesin A Protein.)

Streptococcus Pneumoniae 37-KDa Surface Adhesin A Protein

Sampson, J.; Russell, H.; Tharpe, J.; Ades, E.; Carlone, G. Filed 17 September 1996
Serial No.08/715,131 (Ref # E-157-91/4)

This invention provides the isolated nucleic acid encoding the 37-kDa protein of *Streptococcus pneumoniae* designated pneumococcal surface adhesin A protein (PsaA), formerly designated as pneumococcal fimbrial protein. This invention relates to purified polypeptides encoded by the sequence and a method of measuring the amount of PsaA contained in a sample. This invention also includes a vaccine that may be efficacious in adults or children. (*Portfolio*: Vaccine, Diagnosis, Pneumococcal Surface Adhesin A Protein.)

Use of Human Immortalized Endothelial Cells to Isolate and Propagate Ehrlichia chaffeensis and Ehrlichia canis

Dawson, J. E. Patent Issued: 28 March 95
Patent No. 5,401,656 (Ref # E-155-91/0)

This invention provides a purified immortalized human endothelial cell infected with *Ehrlichia Chaffeensis* or *Ehrlichia canis*. The invention provides a method for simultaneously screening a human subject for *E. Chaffeensis* or *Rickettsia rickettsii*. Also provided is a method of culturing *E. chaffeensis* and *E. Canis*. (*Portfolio*: Diagnosis, Ehrlichiosis, Cell Culture.)

Immunoreactive HTLV-I/II and POL Peptides

Lal, R. B. Patent Issued 3 January 1995
Patent No. 5,378,805 (Ref # E-172-90/0)

This invention relates to a peptide having specific immunoreactivity to antibodies to HTLV-I, HTLV-II derived from the structural gene products from groups consisting of Env-1, Env-2,

Env-5, Gag-1a, and Pol-3. This invention is further directed to an immunoassay method for the detection of antibodies, a peptide composition containing these peptides, and a vaccine. (*Portfolio*: HTLV, Vaccine, Diagnostics.)

Methods and Compositions for Diagnosing HTLV-1 Associated Myelopathy and Adult T-Cell Leukemia

Rudolph, D. L.; Lal, R. B.
Patent Issued 30 May 1995
Patent No. 5,420,244 (Ref # E-206-93/0)

This invention provides antigenic peptides derived from immunodominant epitopes of the HTLV-I *tax* or *rex* proteins that are immunoreactive with antibodies associated with disease in HTLV-I infected subjects. This invention provides peptides corresponding to the immunodominant epitopes of the *rex* regulatory protein of HTLV-I. This invention provides methods for diagnosing HTLV-I associated myelopathy. This invention also provides methods for diagnosing adult T-cell leukemia. (*Portfolio*: HTLV-I, HIV, Antibodies, HAM [HTLV-I Associated Myelopathy], T-cell Leukemia, Diagnosis.)

Isolation of Diagnostic Glycoproteins to Taenia Solium, Immunoblot-assay and Method for the Detection of Human Cysticercosis

Tsang, V. C. W.; Brand, J.; Boyer, A.; Wilson, M.; Schantz, P.; Maddison, S.
Patent Issued 11 October 94
Patent No. 5,354,660 (Ref # E-185-88/1)

This invention is a method and a kit for diagnosing active human neurocysticercosis utilizing an immunoblot assay. This method allows diagnosis of neurocysticercosis by the detection of antigens of larval origin. This invention improves on the specificity and sensitivity of the disc method achieving 98% sensitivity and 100% specificity. This allows the detection of antibodies in the serum or cerebrospinal fluid. (*Portfolio*: Larval Detection, Taenia solium, Neurocysticercosis, Diagnosis.)

Exchangeable Template Reaction

Khudyakov, Y.; Fields, H.
Patent Issued: 2 April 96
Patent No. 5,503,995 (Ref # E-184-91/1)

This invention provides a method of making synthetic DNA of any desired sequence. This invention can be used to make an array of DNA having specific substitution in a known sequence which are expressed and screened for improved function. This invention provides a method for the synthesis of

DNA based on a cyclic mechanism of combining deoxyoligonucleotides. Also included is a kit comprising a series of unique synthesized single-stranded deoxypolynucleotides which can be enzymatically treated to form a unique 3' single-stranded protrusion for selective cyclic hybridization with another unique single-stranded deoxypolynucleotide of the series. (*Portfolio*: DNA, DNA Synthesis.)

Sequences of the Hemagglutinins of Recent Strains of Influenza Type B virus

Rota, P. A.; Hemphill, M. L.
Patent Issued: 20 December 94
Patent No. 5,374,717 (Ref # E-224-92/0)

This invention provides sequence analyses for recent strains of Influenza Type B virus. This invention also provides a method for vaccinating a mammal against influenza type B. This invention also provides a method of detection and diagnosis of an infection with influenza type B virus. (*Portfolio*: Virus, Influenza Type B, Vaccine.)

Method for Detecting Isocyanates

Streicher, R. P.
Patent Issued 11 October 94
Patent No. 5,354,689 (Ref # E-215-92/0)

This invention provides a method for detecting the presence of isocyanate in a sample. Also, the invention provides a method of quantifying the total isocyanate presence by quantifying the reaction product. This invention is particularly well-suited to the detection of isocyanates in air. (*Portfolio*: Isocyanate, Detection.)

Portable Spirometer With Improved Accuracy

Hankinson, J. L.; Viola, J. C.; Ebeling, T. H.
Patent Issued 8 October 96
Patent No. 5,562,101 (Ref # E-030-92/1)

This invention is a spirometric measurement device with an arrangement for computation of a dynamic correction factor to compensate for temperature-related changes. This invention improves the accuracy by increasing the analog-to-digital conversion resolution, by modifying the dithering process, and by compensating for the inherent transducer temperature drift. This invention provides for a multi-functional, downloadable, flexible spirometric device, that requires no disassembly with improved quality control. (*Portfolio*: Spirometric, Lung Capacity, Respiratory Function.)

Dated: May 16, 1997.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-13427 Filed 5-21-97; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Prospective Grant of Exclusive License: Prophylactic Use of Pneumococcal Surface Adhesin A Protein as a Vaccine

AGENCY: Office of Technology Transfer, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent and patent applications referred to below to Connaught Laboratories, Inc. (CLI), having a place of business in Swiftwater, Pennsylvania. The patent rights in these inventions have been assigned to the government of the United States of America. The patent and patent applications to the licensed are:

Title: Pneumococcal Fimbrial Protein A
U.S. Patent Application Serial No.: 07/791,377

Filing Date: 09/17/91

Domestic Status: Patent No.: 5,422,427

Issue Date: 06/06/95

Title: Pneumococcal Fimbrial Protein A and Vaccines
U.S. Patent Application Serial No.: 08/222,179

Filing Date: 09/17/96

Title: Pneumococcal Fimbrial Protein A
U.S. Patent Application Serial No.: 08/356,106

Filing Date: 12/15/94

Title: Streptococcus Pneumoniae 37 kDa Surface Adhesin A Protein
U.S. Patent Application Serial No.: 08/715,131

Filing Date: 09/17/96

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.